AndhraNews.net
Home » Features » Health » Hepatitis C

Hepatitis C


Hepatitis C in News

Biocon Introduces CIMIVIR-L™ for Hepatitis-C in India
Business Wire IndiaBiocon Ltd, Asia's premier biotechnology company, today announced the introduction of an advanced novel therapy CIMIVIR-L™ for the treatment of Hepatitis C in India. CIMIVIR-L™ is a fixed dose combination of Ledipasvir 90 mg and Sofosbuvir 400 mg, which is an equivalent of  the innovator product commercialized by Gilead Sciences in the US

Pharco Pharmaceuticals Inc. Reports Ravidasvir Achieved 100% Cure Rate to Date When Combined with Sofosbuvir for HCV, Non-Cirrhotic, Genotype 4 Patients
Business Wire IndiaEgypt’s leading drug manufacturer Pharco Pharmaceuticals, Inc. announced advanced results today from its Phase III clinical trial of the combination of ravidasvir with sofosbuvir for the treatment of patients with genotype-4 chronic hepatitis C virus, the largest study of its kind globally.

Curb Energy Consumption
(Family Features) Water heaters are energy intensive appliances. In fact, they are the second largest energy user in the home, and as they age, they become less efficient, requiring even more energy.

Before CEOs Pop the Question, They Need to Understand Why Most Mergers Fail and the Secret Behind Those That Succeed
In 2014, companies around the world spent $3.5 trillion on mergers and acquisitions, and merger volume in 2015 is expected to be an all-time record.

PBMI Survey Shows Employers Continue to Face Uphill Battle With Rising Drug Costs
Last year marked a dramatic increase in medication cost trend for employers according to The Pharmacy Benefit Management Institute's (PBMI) fifteenth annual Drug Benefit Report released today. Traditional prescription trend increased from 2.4% to 6.2% and specialty trend increased from 12.2% to 19.2%

Molecular Diagnostics Market Worth $9.50 Billion by 2022: Grand View Research, Inc.
The global molecular diagnostics market is expected to reach over USD 9.50 billion by 2022, according to a new report by Grand View Research Inc. Growing prevalence of chronic diseases and infections such as HPV and influenza is anticipated to be the key driver for molecular diagnostics market growth

Progressive Care Inc.: PharmCo Joins Fight Against Turing Pharmaceuticals With Low-Cost Daraprim Alternative
MIAMI, FL--(Marketwired - December 02, 2015) - Progressive Care Inc

Fish & Richardson Principal Jonathan Singer Named 2015 Life Sciences MVP by Law360
Fish & Richardson today announced that principal Jonathan E. Singer, head of the firm's Life Sciences Practice, has been named a 2015 "Life Sciences MVP" by Law360. According to Law360, Singer is among "those elite attorneys whose successes in high-stakes litigation, record-breaking deals and complex global matters earned them a spot on this year's list of MVP award winners

SuperSonic Imagine to Highlight Advancement in Microvascular Imaging at Annual Radiology Meeting
SuperSonic Imagine (EURONEXT PARIS: SSI) (FR0010526814), the highly innovative ultrasound company, announced today that its new microvascular imaging technology will be showcased at the 101st Scientific Assembly & Annual Meeting of the Radiological Society of North America

Cocrystal Pharma Announces Filing Its Quarterly Financial Statements and Company Update
BOTHELL, WA and ATLANTA, GA--(Marketwired - November 16, 2015) - Cocrystal Pharma, Inc. (OTCQB: COCP),a company focused on developing novel antiviral therapeutics for human diseases, today announced the filing of its quarterly financial statements (10-Q) and provided an update on several of its antiviral programs.

SuperSonic Imagine to Showcase Its Non-Invasive, 60-Second Liver Assessment Exam as an Alternative to Biopsy
SuperSonic Imagine (EURONEXT PARIS: SSI) (FR0010526814), the highly innovative ultrasound company, announced today that the clinical benefits of its ShearWave™ Elastography (SWE™) technology for non-invasive assessment of patients with chronic liver disease will be presented while attending the Liver Meeting® 2015

Theravance Biopharma, Inc. Reports Third Quarter 2015 Financial Results and Provides Business Update
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported financial results for the third quarter ending September 30, 2015. Revenue for the third quarter of 2015 was $10.7 million. Net loss for the third quarter of 2015 was $47.3 million, or $1.40 per share. Cash, cash equivalents, and marketable securities, excluding restricted cash, totaled $196

Sydney Gottlieb-Hirsch Is Presented the Award of Distinction by the International Assoc. of Who's Who
Ms. Sydney Gottlieb-Hirsch is President at Richard Marshall Fine Flooring, Inc., which specializes in custom hardwood handmade flooring.

Theravance Biopharma and Trek Therapeutics Announce Initiation of Phase 2a Trial of TD-6450, an NS5A Inhibitor to Treat Hepatitis C
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Trek Therapeutics ("TREKtx") today announced that TREKtx has initiated a Phase 2a clinical trial of TD-6450, a next-generation investigational NS5A inhibitor in development to treat patients with hepatitis C virus (HCV)

Third quarter marked by volatile markets and increasingly nervous biotech investors
BB BIOTECH AG /Third quarter marked by volatile markets and increasingly nervous biotech investors . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Cocrystal Pharma Announces Late Breaking Abstract at AASLD Liver Meeting
BOTHELL, WA and ATLANTA, GA--(Marketwired - October 15, 2015) - Cocrystal Pharma, Inc

Harvey Alter Receives 2015 Fries Prize for Improving Health
ATLANTA, GA--(Marketwired - October 06, 2015) - Harvey Alter, M.D., M.A.C.P

DirectRx Pharmacy Announces Specialty Pharmacy Accreditation From ACHC
DirectRx (www.DirectRx.com), an independent, specialty pharmacy based in Troy, Mich., today announced it has been awarded the Specialty Pharmacy (SRX) accreditation by the Accreditation Commission for Health Care (ACHC), a national organization developed by homecare and alternate-site healthcare industry providers. The announcement was made by Amanda Berishaj, PharmD, of DirectRx.

FDA expands use of Novartis drug Promacta® to include treatment of children ages 1 and older with chronic immune thrombocytopenia
Novartis International AG /FDA expands use of Novartis drug Promacta® to include treatment of children ages 1 and older with chronic immune thrombocytopenia . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

SuperSonic Imagine Installs Its Aixplorer(R) Ultrasound System at the Universita' Cattolica Del Sacro Cuore's Teaching Hospital in Rome, Italy
SuperSonic Imagine (EURONEXT PARIS: SSI) (FR0010526814), a company specializing in ultrasound medical imaging, today announced the installation of its Aixplorer Ultrasound System at The Agostino Gemelli Teaching Hospital in Rome, Italy

PEH's Portfolio Company Enanta announces U.S. FDA Approval for AbbVie's VIEKIRA PAK(TM)
Private Equity Holding AG /PEH's Portfolio Company Enanta announces U.S. FDA Approval for AbbVie's VIEKIRA PAK(TM) . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Cocrystal Pharma Reports Third Quarter Financial Results and Select Program Updates
BOTHELL, WA--(Marketwired - November 14, 2014) - Cocrystal Pharma, Inc. (the "Company") (OTCQB: COCP), a biotechnology company focused on developing new antiviral therapeutics for human diseases, today reported financial results for the third quarter ended September 30, 2014.

SciClone Reports Financial Results for the Third Quarter 2014
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the third quarter 2014.

Theravance Biopharma, Inc. Reports Third Quarter 2014 Financial Results
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), through its U.S. operating subsidiary, Theravance Biopharma US, Inc., today reported financial results for the third quarter 2014. Revenue for the third quarter of 2014 was $6.3 million. Net loss for the third quarter of 2014 was $54.5 million or $1.72 per share

SciClone to Present at Jefferies Global Healthcare Conference on November 19th
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the Jefferies Global Healthcare Conference on November 19, 2014, at 4:20 pm GMT, taking place at the Waldorf Hilton Hotel in London, England.

Theravance Biopharma Announces Positive Results From Phase 1 Proof-of-Concept Study of TD-6450, an NS5A Inhibitor to Treat Hepatitis C
Theravance Biopharma (NASDAQ: TBPH), through its U.S. operating subsidiary, Theravance Biopharma US, Inc., today announced positive results from the first three cohorts of Study 0110, a Phase 1 proof-of-concept study of TD-6450, a next-generation investigational NS5A inhibitor in development to treat patients with hepatitis C virus infection (HCV).

SciClone Pharmaceuticals to Report Financial Results for the Third Quarter 2014 on November 10th
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the third quarter 2014 on Monday, November 10, 2014. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET (1:30 pm PT) that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Wilson W

Biotech bucks macro uncertainties - strong quarterly results for BB Biotech
BB BIOTECH AG /Biotech bucks macro uncertainties - strong quarterly results for BB Biotech. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Health Center Leaders Discuss Leveraging Telehealth Innovation to Affect Organization Change
MIDDLETOWN, CT--(Marketwired - September 25, 2014) - Community Health Center, Inc.'s (CHC) President and CEO, Mark Masselli, and VP/Chief Quality Officer, and Director of CHC's Weitzman Institute, Dr

SciClone to Present at BioCentury NewsMakers in the Biotech Industry Conference on September 26, 2014
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, PhD, Chief Executive Officer, will present a corporate overview and business update at the 2014 BioCentury NewsMakers in the Biotech Industry conference at 11:30 am ET on Friday, September 26, 2014, at the Millennium Broadway Hotel & Conference Center in New York City.

Hetero Enters License Agreement With Gilead Sciences Inc., USA to Produce Generic Sofosbuvir for Treatment of Chronic Hepatitis C
Hetero Group, today announced that it has obtained licensing rights to manufacture and market sofosbuvir and combination drug ledipasvir/sofosbuvir upon approval from Gilead Sciences Inc., USA for 90 countries

SciClone to Present at Aegis 2014 Healthcare & Technology Conference on September 11, 2014
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the Aegis Capital Corp. 2014 Healthcare & Technology Conference at 10:45 am PT on Thursday, September 11, 2014, at The Encore at Wynn in Las Vegas.

SciClone and BTG Announce That DC Bead(R) Has Been Approved by China Food and Drug Administration
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN), and its partner BTG plc (LSE: BTG), today announced that the China Food and Drug Administration has approved the registration of DC Bead® for the embolization of malignant hypervascularized tumors.

Cocrystal Pharma Reports Second Quarter Financial Results
BOTHELL, WA--(Marketwired - August 15, 2014) - Cocrystal Pharma, Inc. (the "Company") (OTCBB: COCP) (OTCQB: COCP), a biotechnology company developing new antiviral therapeutics for human diseases, today reported financial results for the second quarter ended June 30, 2014.

Healthy Trucking Association of America, OraSure Technologies and AbbVie Team Up to Launch Hepatitis C Awareness Campaign at The Great American Trucking Show
The Healthy Trucking Association of America (HTAA), OraSure Technologies, Inc. (NASDAQ: OSUR) and AbbVie today announced they have joined forces to launch Truckers Rolling Against Hepatitis C, a nationwide initiative to educate truck drivers about the hepatitis C virus (HCV) and encourage testing among this population

SciClone Reports Financial Results for the Second Quarter 2014
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the second quarter 2014.

International Antiviral Therapeutics Report 2014-Technologies, Markets and Companies (Updated)
Research and Markets (http://www.researchandmarkets.com/research/rmhmmj/antiviral) has announced the addition of a new report "Antiviral Therapeutics - Technologies, Markets and Companies" to their offering.

SciClone Pharmaceuticals to Report Financial Results for the Second Quarter 2014 on August 11th
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the second quarter 2014 on Monday, August 11, 2014. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET (1:30 pm PT) that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Wilson W

BB BIOTECH AG: Biotech sector recovers from market correction - new products and M&A the main drivers
BB BIOTECH AG /BB BIOTECH AG: Biotech sector recovers from market correction - new products and M&A the main drivers . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

India HIV/AIDS Alliance at the 20th International AIDS Conference (AIDS 2014) 20-25 July 2014, Melbourne, Australia
India HIV/AIDS Alliance is at the 20th International AIDS Conference (AIDS 2014) to highlight how vulnerable and marginalised populations most at risk in the HIV epidemic remain stigmatised, discriminated against and criminalised.  As a result, millions are denied their human rights and essential access to basic health services

Recap of NanoViricides, Inc. CEO Dr. Eugene Seymour Clear Channel Business Talk Radio Interview
NanoViricides, Inc. (NYSE MKT: NNVC) is a development stage company that is creating special purpose nanomaterials to destroy viruses in and on the body. The Company today announced that Michael Yorba of Clear Channel's Business Talk Radio Show, The Traders Network, interviewed CEO Dr. Eugene Seymour live on December 19, 2013.

NanoViricides CEO Dr. Eugene Seymour to Be Interviewed on Clear Channel DFW 1190AM
NanoViricides, Inc. (NYSE MKT: NNVC) is a development stage company that is creating special purpose nanomaterials to destroy viruses in and on the body. The Company announced today that CEO Dr. Eugene Seymour will be interviewed live by Michal Yorba on Clear Channel Business Talk Radio's Traders Financial Network, Thursday, December 19th, 2013, at 2:00pm CST / 12:00pm PST / 3:00pm EST.

SciClone to Present at Oppenheimer Healthcare Conference on December 10, 2013
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the Oppenheimer 24th Annual Healthcare Conference on Tuesday, December 10, 2013, at 3:20 pm ET at the Crowne Plaza Hotel in New York.

Biozone Pharmaceuticals Announces Executed Letter of Intent to Merge With Cocrystal Discovery Inc.
ENGLEWOOD CLIFFS, NJ--(Marketwired - November 27, 2013) - Biozone Pharmaceuticals, Inc. (OTCBB: BZNE) today announced that it has agreed to terms and signed a Letter of Intent to merge with Cocrystal Discovery, Inc., a privately-held, biotechnology company developing antiviral therapeutics for human diseases

SCYNEXIS Appoints Vivian Doelling as Vice President of Animal Health
Drug discovery company SCYNEXIS, Inc. today announced the appointment of Dr. Vivian Doelling as Vice President of Animal Health. Doelling is an industry leader in the field of animal health with more than 20 years of experience.

Biozone Announces First Step in Strategic Transition
ENGLEWOOD CLIFFS, NJ--(Marketwired - November 13, 2013) - Biozone Pharmaceuticals, Inc. (OTCQB: BZNE), a manufacturer of over-the-counter (OTC) pharmaceuticals, and skin care, cosmetic and beauty products, and developer of proprietary drug delivery platforms, issued the following Letter to Shareholders from Elliot Maza, Chief Executive Officer and CFO of the company.

SciClone Reports Financial Results for the Three and Nine Months Ended September 30, 2013
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the third quarter and for the nine months ended September 30, 2013.

Fuzheng Huayu (FZHY) Completed Phase II Clinical Trial for Treatment of Liver Fibrosis in Patients With Chronic Hepatitis C
Shanghai Sundise Traditional Chinese Medicine Co. Ltd today released its multi-center, double-blinded, placebo-controlled clinical phase II trial results at a satellite symposium during the 2013 annual meeting of American Association for Study of Liver Diseases (AASLD®)

SciClone Pharmaceuticals to Report Financial Results for the Third Quarter, 2013 on November 12th
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the third quarter, 2013 on Tuesday, November 12, 2013. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Wilson W

Q&A With Chairman and CEO of Aethlon Medical (OTCQB: AEMD) Discussing Launch of New Subsidiary, Exosome Sciences, Inc.
Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and medical technology stocks, issues an exclusive Q&A with Jim Joyce, Chairman and CEO of Aethlon Medical, Inc. (OTCQB: AEMD). Mr. Joyce discusses the recent launch of its new Exosome Sciences, Inc. (ESI) and what that potentially represents to Aethlon and its shareholders.

SciClone Appoints Nancy T. Chang, Ph.D., to Its Board of Directors
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Nancy T. Chang, Ph.D., has been appointed a member of the Company's board of directors. Dr. Chang has more than 30 years of experience in the pharmaceutical and biotechnology industry, and has successfully developed and commercialized multiple therapeutic and diagnostic products

Elsevier Business Intelligence Releases the Top BioPharma Projects to Watch List
Elsevier Business Intelligence announces the 2013 Top Projects to Watch and the companies confirmed to present at Therapeutic Area Partnerships (TAP) being held at Hyatt Regency in Boston from November 18th - 20th.

Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr. David Suhy to Regen BioPharma Inc.'s Scientific Advisor Board
Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced that it has recruited, Dr. David Suhy, a pioneer in the field of RNA Interference (RNAi), to join the Scientific Advisory Board of Regen BioPharma Inc. ("Regen"), a subsidiary of Bio-Matrix Scientific Group Inc.

Hepatitis C: Phase III data show Boehringer Ingelheim’s faldaprevir* is effective even in patients with common drug-resistant viral variant
For media outside of the US, the UK & Canada only

Hepatitis C: Boehringer Ingelheim's faldaprevir granted accelerated assessment from European Medicines Agency
For media outside of the U.S.A., UK and Canada only

Phase III data show Boehringer Ingelheim's faldaprevir* was highly effective in a broad range of patients with genotype-1 hepatitis C
For media outside of the U.S.A., UK and Canada only

Investigational interferon-free regimen demonstrates undetectable hepatitis C virus in all patients reaching end of treatment in ongoing Phase II trial

Boehringer Ingelheim broadens efforts for interferon-free hepatitis C treatments through clinical collaboration with Presidio Pharmaceuticals

Boehringer Ingelheim's interferon-free hepatitis C treatment portfolio strengthened by promising Phase II data
For media outside of the U.S.A., UK and Canada only

36 Year Old Undergoes 16 Hour Liver Transplant Surgery at HCG, Gets a New Lease of Life
HCG Hospitals, organized a press conference on treating 36 year old Indian from USA, diagnosed with liver cirrhosis, underwent marathon 16 hour liver transplant surgery, with the organ donated from his wife. A year ago, the patient had weakness and loss of appetite. During his routine health check-ups, he was diagnosed with liver cirrhosis, due to autoimmune hepatitis

As Competitors Pursue Alternatives Medgenics' INFRADURE Gains Prominence for its Potential to Treat Hepatitis
Medgenics' (NYSEAMEX: MDGN) INFRADURE(TM) provides sustained productionand delivery of interferon-alpha for the treatment of hepatitis. INFRADURE(TM) is a kind of miniature pump that is impacted into the patient and continuously produces and release the desired protein into the patient's system

MMRGlobal Files Form 8-K Regarding Signing of Patent License Agreement, Dr. Shekhar Challa to Medical Board of Advisors
MMRGlobal, Inc. (OTCQB: MMRF) today announced it filed a Form 8-K regarding the signing by MyMedicalRecords, Inc. (MMR) of a Non-Exclusive Patent License Agreement with 4medica, Inc. to license U.S. rights for the health IT patents owned by MyMedicalRecords, Inc. These include but are not limited to U.S

Melbourne University and Bio Farma to Jointly Develop Vaccine Adjuvant
Melbourne University has announced an agreement with Indonesian vaccine maker Bio Farma to develop a vaccine delivery system that can boost the vaccine effectiveness for a range of infectious diseases, including Hepatitis C, Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemopilus influenza type-B."Bio Farma is proud to collaborate with the University of Melbourne

Final Regulatory Approvals Received for International Study to Reboost Patients From the Completed Vacc-4x Phase II Trial
Bionor Pharma ASA (OSLO: BIONOR)

SciClone to Present at Oppenheimer 23rd Annual Healthcare Conference on December 13th
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Chief Executive Officer, will present a corporate overview and business update at the Oppenheimer 23rd Annual Healthcare Conference on December 13, 2012 at 11:10 am ET at the Waldorf-Astoria Hotel in New York City.

SciClone Announces New ZADAXIN(R) Anti-Counterfeiting Label Wins Major Industry Award
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that its newly created anti-counterfeiting Pharma-Comb Void label for ZADAXIN has won the prestigious "Innovator Award" in the annual competition sponsored by the Tag and Label Manufacturers Institute (TLMI)

Octoplus publishes third quarter business update
Leiden, the Netherlands, 15 November 2012 - OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO) today publishes its business update for the third quarter of 2012.

PropThink: Does Achillion Have a Place in the HCV Market of the Future?
By Ivan DeryuginThe biotechnology sector is one where growth is, for the most part, fueled by a single factor: new drugs. Companies that develop the next generation of drugs for a market stand to gain billions over the life cycle of that drug. And no health market embodies that more than the hepatitis C (HCV) market

Biota Pharmaceuticals Announces Appointment of New Executive Officers
Biota Pharmaceuticals, Inc. (NASDAQ: BOTA) today announced the appointment of Russell H. Plumb as its Chief Executive Officer and Joseph M. Patti, M.S.P.H., Ph.D. as Executive Vice President, Corporate Development & Strategy. Mr. Plumb will also join the Board of Directors.

PropThink: Lightweight Contender ACHN Declines on Gilead's Latest Hepatitis Data
By Jake KingWith Gilead's (NASDAQ:GILD) reported 100% Hepatitis C virologic response rate over the weekend, rivals Achillion (NASDAQ:ACHN) and Vertex (NASDAQ:VRTX) traded down 15% and 5% respectively at Monday's open. Vertex shareholders rightfully have cause for alarm, as Incivek's blockbuster status may shortly be replaced by more effective oral treatments

PropThink: Lightweight Contender ACHN Declines on Gilead's Latest Hepatitis Data
By Jake King

SciClone to Present at Lazard Capital Markets 9th Annual Healthcare Conference on November 14th
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Gary Titus, Chief Financial Officer, will present a corporate overview and business update at the Lazard Capital Markets 9th Annual Healthcare Conference on November 14, 2012 at 2:00 pm ET at the Pierre Hotel in New York City.

Novartis new two-year data with Certican® shows positive outcomes at 24 months in largest liver transplant trial to date
Novartis International AG /Novartis new two-year data with Certican® shows positive outcomes at 24 months in largest liver transplant trial to date . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

GI-5005 Improves Virologic Clearance of HCV in Combination with PegIFN/Ribavirin in IL28B T/T Patients
Clinical Trial Data to be Presented at The Liver Meeting® 2012 in BostonBOSTON, Nov. 11, 2012 - GlobeImmune, Inc

PropThink: Biogen Idec: rFVIIIFc Trials Somewhat Disappointing, but ALS Trials Could be the Next Catalyst
By Ivan DeryuginThe past few months have been eventful ones for Biogen Idec (NASDAQ:BIIB), as the company awaits the FDA's decision on BG-12 and continues to build out is pipeline. Last week, Biogen reported new Phase III data for its hemophilia A drug, rFVIIIFc

SciClone Reports Financial Results for the Third Quarter 2012 and 2012 Outlook
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the third quarter and for the nine months ended September 30, 2012

Direction Change Ahead, What to Expect - Research & Analysis on Marathon Oil Corporation and Marathon Petroleum Corporation
Moments ago, TradersInsight.net introduced new coverage of Marathon Oil Corporation (NYSE: MRO) and Marathon Petroleum Corporation (NYSE: MPC). Full outlook, analysis and consensus opinion is available to readers via the links below.

SciClone Pharmaceuticals to Report Financial Results for the Third Quarter 2012 and 2012 Outlook on November 9th
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report third quarter 2012 financial results and 2012 outlook on Friday, November 9, 2012. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET that day. The call will be hosted by Friedhelm Blobel, Ph.D

SCYNEXIS’ Oral SCY-635 Shows Potential as an Immune Acting Antiviral to Augment Current HCV Treatments
SCYNEXIS, Inc

Boehringer Ingelheim’s interferon-free all-oral hepatitis C treatment+ shows up to 85% viral cure in Phase IIb study including patients with advanced liver disease
For media outside of the U.S.A. , UK and Canada only

Peregrine Provides Update on HCV Clinical Program
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today provided an update from its randomized Phase II bavituximab study in patients infected with genotype-1 chronic hepatitis C virus (HCV)

Former Assistant U.S. Surgeon General Roscoe M. Moore, Jr., DVM, PhD, MPH Joins the BioMedical Technology Solutions Scientific Advisory Board
BioMedical Technology Solutions Holdings, Inc. ("BMTS," "the Company") (OTCBB: BMTL) announced today the addition of former Assistant U.S. Surgeon General Roscoe M. Moore, Jr., DVM, PhD, MPH to its Scientific Advisory Board.

SciClone Pharmaceuticals Announces Final Settlement of Stockholder Derivative Litigation
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the California Superior Court for the County of San Mateo has granted final approval of a settlement reached by the parties to the consolidated derivative lawsuits against certain of its current and former directors and officers of SciClone Pharmaceuticals, and against SciClone as a nominal defendant.

A Change in Tides - Featured Research on Scripps Networks Interactive, Inc. and Toyota Motor Corporation (ADR)
Today, www.BollingerReport.com introduced featured coverage of Scripps Networks Interactive, Inc. (NYSE: SNI) and Toyota Motor Corporation (ADR) (NYSE: TM). Full research reports are available to readers at: www.BollingerReport.com/index.php?sm1=SNI&sm2=TM.

Peregrine Pharmaceuticals Reports Second Quarter 2012 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced financial results for the second quarter ended October 31, 2011 of fiscal year (FY) 2012 and provided an update on its advancing clinical pipeline and other corporate developments.

Peregrine's Bavituximab Shows 50% Improvement in Overall Tumor Response Rate in Randomized Phase II Lung Cancer Trial
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced preliminary results from a randomized Phase II trial showing a 50% improvement in overall tumor response rates (ORR) in non-small cell lung cancer (NSCLC) patients

Peregrine to Report Second Quarter Fiscal Year 2012 Financial Results After Market on December 12, 2011
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it will report financial results for the second quarter of the fiscal year 2012 on December 12, 2011 after market and will host a conference call and webcast at 1:30 PM PST (4:30 PM EST)

Etta James in final stages of 'incurable' leukaemia
Iconic soul singer Etta James is suffering from incurable leukaemia and is now terminally ill, her live-in doctor has revealed.

'Pep talk' can revive immune cells worn out by chronic viral infection
Immune cells exhausted from chronic infections by viruses can be revived after the introduction of fresh cells that act like coaches giving a "pep talk", a new study has claimed.

Boehringer Ingelheim completes patient entry for Phase III trial programme in Hepatitis C
For media outside of the U.S.A. only

Comment on this story

Share